Discriminant analysis in the clinical and biochemical diagnosis of primary liver cancer.
Discriminant analysis was used in evaluating the importance of clinical aspects and the value of routine and experimental biochemical markers in the differential diagnosis of primary liver cancer (PLC) and chronic, non-neoplastic, liver diseases. Our results show that: 1) Clinical signs, such as the presence of pain, weight loss or mass, correctly indicate the diagnosis in 76% of the cases; 2) The determination of alkaline phosphatase isoenzymes is shown by the computer to be the most useful marker and provides an overall diagnostic accuracy which is higher than that of alpha-fetoprotein. We also found that, by using these two markers together, "by intersection," the best overall accuracy (85%) is obtained. We, therefore, suggest determination of alkaline phosphatase isoenzymes and alpha-fetoprotein in screening the populations at risk for liver cancer.
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000032:analysis; D001835:Body Weight; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis*; D003201:Computers; D003937:Diagnosis, Differential; D005260:Female; D006505:Hepatitis / Q000175:diagnosis; D006801:Humans; D007527:Isoenzymes / Q000032:analysis; D008103:Liver Cirrhosis / Q000175:diagnosis; D008107:Liver Diseases / Q000175:diagnosis*; D008113:Liver Neoplasms / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D010146:Pain; D000509:alpha-Fetoproteins / Q000032:analysis
D007527:Isoenzymes; D000509:alpha-Fetoproteins; D000469:Alkaline Phosphatase